Table 3.
PCWG2-PSA, RECIST 1.1, PERCIST 1.0 response evaluation at 4th month follow-up
| Variables | Metastatic castrate-resistant prostate cancer (N=47) | ||
|---|---|---|---|
| n or median | % | ||
| 4th Month Disease Evaluation: PSA | |||
| CR | 3 | 6 | |
| PR | 19 | 40 | |
| SD | 8 | 17 | |
| PD | 16 | 34 | |
| PSA <0.2 at Baseline and 4th month | 1 | 2 | |
| 4th Month Disease Evaluation: RECIST 1.1 1 | |||
| # of Patients WITH Target Lesions at Baseline | 19 | 51 | |
| # of Target Lesions: Median (Min, 25%, 75%, Max) | 2 (1, 1, 3, 5) | ||
| # of Non-Target Lesions: Median (Min, 25%, 75%, Max) | 5 (0, 2, 10, 21) | ||
| Total # of Lesions: Median (Min, 25%, 75%, Max) | 8 (1, 4, 11, 22) | ||
| Overall Response Evaluation | |||
| CR | 1 | ||
| PR | 9 | ||
| SD | 5 | ||
| PD | 4 | ||
| # of Patients WITHOUT Target Lesions | 18 | 49 | |
| # of Non-Target Lesions: Median (Min, 25%, 75%, Max) | 5 (0, 1, 10, 20) | ||
| Response Evaluation (non-Target lesions) | |||
| CR | 3 | ||
| Non-CR/non-PD | 11 | ||
| PD | 4 | ||
| 4th Month Disease Evaluation: PERCIST 1.0 1 | |||
| # of Target Lesions: Median (Min, 25%, 75%, Max) | 3 (0, 1, 5, 5) | ||
| # of Non-Target Lesions: Median (Min, 25%, 75%, Max) | 3 (0, 0, 6, 18) | ||
| Total # of Lesions: Median (Min, 25%, 75%, Max) | 6 (0, 2, 11, 23) | ||
| MAX SUL: Median (Min, 25%, 75%, Max) | 3.6 (0, 2.1, 5.1, 10.6) | ||
| Overall Response Evaluation | |||
| CMR | 4 | 9 | |
| PMR | 11 | 23 | |
| SMD | 10 | 21 | |
| PMD | 19 | 40 | |
| Not Evaluable by PERCIST 1.0 2 | 3 | 6 | |
| Occurrence of New Lesions | 12 | 26 | |
1 For patients with extensive number of bone lesions, not all bone lesions were counted or measured for disease evaluation. 2 Patients not evaluable with PERCIST 1.0 due to not having any target or non-target lesions or new lesions based on PERCIST 1.0.